Detalhe da pesquisa
1.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469184
2.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36756959
3.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37585665
4.
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Eur Urol
; 78(6): 847-853, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010985